BioSpace News Archive

Life Spine announced that it has received clearance from the U.S. Food & Drug Administration to market the GHOST 3D-Printed Titanium Spacer Systems.

Medikine to Present Preliminary Phase 1 Clinical Trial Results for MDK-703 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022).

Certis Oncology Solutions, a life science technology company, announced today the release of its new cancer model database, BarneyOI™.

Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled " Enhancement of T Cell Homing to Tumors Through Augmentation of Chemokine Responsiveness and Activation Dependent Chemokine Secretion” with the United States Patent and Trademark Office.

Waters Corporation will hold its Q3 2022 financial results conference call live on Tuesday, November 1st 2022 at 8:00 a.m. eastern time.

Adaptive Biotechnologies Corporation today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Century Therapeutics today announced that preclinical data from the Company’s iPSC-based cell therapy platform will be presented in two posters at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, on November 8-12, 2022 in Boston, Massachusetts.

Fusion Pharmaceuticals Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 195,000 shares of its common stock to five employees outside Fusion’s 2020 Stock Option and Incentive Plan.

Colossal Biosciences, a breakthrough genetic engineering and de-extinction company, accelerates efforts to end elephant extinction on Earth.

Diabetes is one of the most prevalent chronic diseases in Canada with over 3 million people with diabetes in the country and 200,000 new cases diagnosed every year.